Pulsenmore prices $7.5M private placement with institutional investor

Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM) has entered into a securities purchase agreement for a private placement expected to raise approximately $7.5 million in gross proceeds, before placement agent commissions and other offering expenses, according to a company statement.

The offering involves 1,562,500 ordinary shares, or pre-funded warrants in lieu thereof, along with ordinary warrants to purchase up to 1,562,500 additional ordinary shares. The combined purchase price is $4.80 per ordinary share and accompanying warrant, or $4.7999 per pre-funded warrant and accompanying ordinary warrant. The company said the price represents a premium to the Nasdaq Minimum Price under Nasdaq rules.

The ordinary warrants carry an exercise price of $4.80 per share, are exercisable immediately upon issuance, and expire five years from the date of issuance. The pre-funded warrants have an exercise price of $0.0001 per share and are exercisable immediately until exercised in full.

The offering is being sold to a single healthcare-focused institutional investor. A.G.P./Alliance Global Partners is acting as the sole placement agent. Closing is expected on or about June 26, 2026, subject to customary closing conditions.

Pulsenmore said it intends to use net proceeds for marketing and commercialization activities, working capital, and general corporate purposes. Chief Executive Officer Elazar Sonnenschein said the financing is intended to support U.S. market expansion and other strategic initiatives.

The securities are being offered under an exemption from registration pursuant to Section 4(a)(2) of the Securities Act of 1933 and/or Regulation D. Pulsenmore has agreed to file a registration statement with the U.S. Securities and Exchange Commission covering the resale of the shares.

You May Also Be Interested In

• Mint Incorporation closes $2.5M registered direct offering
• NeOnc reports Phase 2a brain cancer trial results, plans FDA meeting
• Kazia Therapeutics launches public offering of ADS and warrants